Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7494523 | 1.00 | ACHE (0.67) | ACHETSHRMEN1THRBHTT | |
| SCHEMBL10580452 | 0.98 | ACHE (0.69) | ACHETSHR | |
| SCHEMBL10583462 | 0.92 | ACHE (0.69) | ACHEMEN1THRBHTTKMT2A | |
| SCHEMBL22281952 | 0.90 | ACHE (0.61) | ACHEMEN1KMT2A | |
| SCHEMBL5248138 | 0.88 | ACHE (0.80) | ACHETSHRMEN1THRBHTT | |
| SCHEMBL5246263 | 0.88 | ACHE (0.80) | ACHETSHRMEN1THRBHTT | |
| SCHEMBL10817672 | 0.86 | ACHE (0.73) | ACHE | |
| SCHEMBL34474386 | 0.85 | ACHE (0.57) | ACHE | |
| SCHEMBL30733875 | 0.85 | ACHE (0.57) | ACHE | |
| SCHEMBL30786561 | 0.85 | ACHE (0.57) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11318205-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11318205-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | ACHE 2778/4885TSHR 3319/4885MEN1 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.